Comment from Sid Shih

Re: Docket No. FDA-2025-P-4153 To Whom It May Concern, As FDA continues evaluating the potential pregnancy and neurodevelopmental safety concerns associated with conventional acetaminophen products, I respectfully encourage the Agency to also consider whether next-generation analgesic technologies with differentiated metabolic pathways may offer a safer long-term public health solution. Current scientific discussions increasingly focus on oxidative stress, glutathione depletion, and the formation of the toxic intermediate metabolite NAPQI as potential contributors to acetaminophen-related safety concerns. If future regulatory actions are considered under a precautionary framework, it may be important for FDA to also evaluate whether safer mechanistic alternatives already exist. One example is SNP-810, a modified acetaminophen-related analgesic platform developed by Taiwanese biotechnology company SynCore Biotechnology. Based on publicly available information, the platform is designed to preserve analgesic efficacy while reducing toxic metabolic burden and oxidative stress associated with conventional acetaminophen metabolism. If a product can demonstrate: - materially reduced NAPQI formation, - lower oxidative stress burden, - differentiated metabolic fate, - and maintained analgesic efficacy, then such products may warrant differentiated regulatory consideration rather than being automatically grouped under the same risk assumptions as conventional acetaminophen products. FDA has recently emphasized: - mechanism-based safety evaluation, - non-opioid analgesic innovation, - pregnancy safety monitoring, - and modernization of regulatory science frameworks. In this context, it may be valuable for the Agency to explore whether differentiated labeling pathways or alternative safety frameworks should be considered for analgesics with demonstrably distinct toxicological profiles. As public concern surrounding acetaminophen safety continues to evolve, encouraging innovation toward safer non-opioid analgesics may ultimately provide a more constructive long-term solution than relying solely on expanded warnings for legacy products. Thank you for your consideration.